Ability of Interleukin‐33– and Immune Complex–Triggered Activation of Human Mast Cells to Down‐Regulate Monocyte‐Mediated Immune Responses. Issue 9 (September 2015) - Rivellese, Felice
Abstract Objective Mast cells have been implicated in the pathogenesis of rheumatoid arthritis (RA). In particular, their activation by interleukin‐33 (IL‐33) has been linked to the development of arthritis in animal models. The aim of this study was to evaluate the functional responses of human mast cells to IL‐33 in the context of RA. Methods Human mast cells were stimulated with IL‐33 combined with plate‐bound IgG or IgG anti–citrullinated protein antibodies (ACPAs), and their effects on monocyte activation were evaluated. Cellular interactions of mast cells in RA synovium were assessed by immunofluorescence analysis, and the expression of messenger RNA (mRNA) for mast cell–specific genes was evaluated in synovial biopsy tissue from patients with early RA who were naive to treatment with disease‐modifying antirheumatic drugs. Results IL‐33 induced the up‐regulation of Fcγ receptor type IIa and enhanced the activation of mast cells by IgG, including IgG ACPAs, as indicated by the production of CXCL8/IL‐8. Intriguingly, mast cell activation triggered with IL‐33 and IgG led to the release of mediators such as histamine and IL‐10, which inhibited monocyte activation. Synovial mast cells were found in contact with CD14+ monocyte/macrophages. Finally, mRNA levels of mast cell–specific genes were inversely associated with disease severity, and IL‐33 mRNA levels showed an inverse correlation with the levels of proinflammatory markers. Conclusion When human mast cells are activated by IL‐33, an immunomodulatory phenotype develops, with human mast cells gaining the ability to suppress monocyte activation via the release of IL‐10 and histamine. These findings, together with the presence of synovial mast cell–monocyte interactions and the inverse association between the expression of mast cell genes at the synovial level and disease activity, suggest that these newly described mast cell–mediated inhibitory pathways might have a functional relevance in the pathogenesis of RA.